Tokyo Joe's Cafe / Societe Anonyme Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: HandsOn who wrote (8326)	8/11/1998 9:30:00 AM
From: Leman	Read Replies (1) of 8798

BMRA news Biomerica Announces New Patent for the Technology it is Using to Develop Tests for Ulcers and Stomach Cancer NEWPORT BEACH, Calif., Aug. 11 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news) announced today that the U.S. Patent Office has issued a new patent for the technology it is licensing to develop an exclusive new generation of tests for detecting highly virulent strains of Helicobacter pylori bacteria. The virulent strains of this bacterium cause peptic ulcers and can lead to stomach cancer if untreated. The patent describes a method for detecting antibodies against the CagA protein expressed only by virulent strains of H. pylori. Unlike other H. pylori tests, this second-generation test will pinpoint individuals who have strains of the bacterium that can cause the greatest damage in the body. ''We are moving forward quickly to develop simple and easy to perform tests using this technology for laboratories, hospitals and physicians' offices,'' said Zackary Irani, Biomerica Chief Executive Officer. Biomerica was the first company in the world to develop a commercial laboratory blood test to detect the presence of antibodies to H. pylori. ''We are developing the first test that will allow physicians to specifically identify high risk individuals who require immediate treatment. The test will require only a blood sample and can be performed at almost any clinical laboratory or physicians' office,'' Irani said. H. pylori infection has been called the world's most prevalent disease, affecting as much as 70 percent of the world's population and one in three Americans. Biomerica (Nasdaq: BMRA - news) is a global medical company devoted to developing, manufacturing and marketing advanced medical diagnostics products for the early detection of diseases. These products are used in hospitals, physicians' offices and in the home for self-testing. This press release contains forward looking information that is based on current expectations and therefore it necessarily involves risk and uncertainties. Although the Company believes that the basis for the forward looking statements are reasonable, there can be no assurance that the results anticipated in the forward looking statements will be realized. Mary factors could influence the results contemplated and therefore there is no assurance that the company's products will become commercially successful.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next